88 related articles for article (PubMed ID: 9584052)
1. Correlation of prostate specific antigen immunoactivity (IR-PSA) to other prognostic factors in female breast cancer.
Griniatsos J; Diamantis E; Gioti J; Karyda I; Vassilopoulos PP; Agnanti N
Anticancer Res; 1998; 18(1B):683-8. PubMed ID: 9584052
[TBL] [Abstract][Full Text] [Related]
2. Prostate-specific antigen is a new favorable prognostic indicator for women with breast cancer.
Yu H; Giai M; Diamandis EP; Katsaros D; Sutherland DJ; Levesque MA; Roagna R; Ponzone R; Sismondi P
Cancer Res; 1995 May; 55(10):2104-10. PubMed ID: 7538047
[TBL] [Abstract][Full Text] [Related]
3. Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate-specific antigen in combination.
Yu H; Levesque MA; Clark GM; Diamandis EP
Br J Cancer; 1999 Oct; 81(3):490-5. PubMed ID: 10507775
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical analysis of prostate-specific antigen does not correlate to other prognostic factors in breast cancer.
Heyl W; Wolff JM; Biesterfeld S; Schröder W; Zitzelsberger D; Jakse G; Rath W
Anticancer Res; 1999; 19(4A):2563-5. PubMed ID: 10470195
[TBL] [Abstract][Full Text] [Related]
5. Expression of prostate-specific antigen (PSA) correlates with poor response to tamoxifen therapy in recurrent breast cancer.
Foekens JA; Diamandis EP; Yu H; Look MP; Meijer-van Gelder ME; van Putten WL; Klijn JG
Br J Cancer; 1999 Feb; 79(5-6):888-94. PubMed ID: 10070886
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of prostate-specific antigen for women with breast cancer: a large United States cohort study.
Yu H; Levesque MA; Clark GM; Diamandis EP
Clin Cancer Res; 1998 Jun; 4(6):1489-97. PubMed ID: 9626467
[TBL] [Abstract][Full Text] [Related]
7. Prostate-specific antigen value as a marker in breast cancer.
Narita D; Cimpean AM; Anghel A; Raica M
Neoplasma; 2006; 53(2):161-7. PubMed ID: 16575473
[TBL] [Abstract][Full Text] [Related]
8. Prostate specific antigen (PSA) in breast and ovarian cancer.
Kucera E; Kainz C; Tempfer C; Zeillinger R; Koelbl H; Sliutz G
Anticancer Res; 1997; 17(6D):4735-7. PubMed ID: 9494598
[TBL] [Abstract][Full Text] [Related]
9. Is prostate-specific antigen (PSA) density better than the preoperative PSA level in predicting early biochemical recurrence of prostate cancer after radical prostatectomy?
Jones TD; Koch MO; Bunde PJ; Cheng L
BJU Int; 2006 Mar; 97(3):480-4. PubMed ID: 16469012
[TBL] [Abstract][Full Text] [Related]
10. [Studies on recurrent breast cancer--clinicopathological factors and p53, p21Cip1/Waf1 and cyclin D1 protein expression].
Yamaguchi Y; Hirooka Y; Konishi I; Sato N; Suzuki K; Kaibara N
Gan To Kagaku Ryoho; 1999 Apr; 26(5):673-7. PubMed ID: 10234299
[TBL] [Abstract][Full Text] [Related]
11. Polyadenylate polymerase enzymatic activity in mammary tumor cytosols: A new independent prognostic marker in primary breast cancer.
Scorilas A; Talieri M; Ardavanis A; Courtis N; Dimitriadis E; Yotis J; Tsiapalis CM; Trangas T
Cancer Res; 2000 Oct; 60(19):5427-33. PubMed ID: 11034084
[TBL] [Abstract][Full Text] [Related]
12. Prostate-specific antigen may serve as a pathological predictor in breast cancer.
Nariţa D; Anghel A; Motoc M
Rom J Morphol Embryol; 2008; 49(2):173-80. PubMed ID: 18516323
[TBL] [Abstract][Full Text] [Related]
13. p53 mutation in plasma DNA and its prognostic value in breast cancer patients.
Shao ZM; Wu J; Shen ZZ; Nguyen M
Clin Cancer Res; 2001 Aug; 7(8):2222-7. PubMed ID: 11489795
[TBL] [Abstract][Full Text] [Related]
14. Tumor histology and stage but not p53, Her2-neu or cathepsin-D expression are independent prognostic factors in breast cancer patients.
Korkolis DP; Tsoli E; Fouskakis D; Yiotis J; Koullias GJ; Giannopoulos D; Papalambros E; Nikiteas NI; Spiliopoulou CA; Patsouris E; Asimacopoulos P; Gorgoulis VG
Anticancer Res; 2004; 24(3b):2061-8. PubMed ID: 15274401
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of p53 and X-ray repair cross-complementing group 1 polymorphisms on prostate-specific antigen recurrence in prostate cancer post radical prostatectomy.
Huang SP; Huang CY; Wang JS; Liu CC; Pu YS; Yu HJ; Yu CC; Wu TT; Huang CH; Wu WJ; Chou YH; Wu MT
Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6632-8. PubMed ID: 18006764
[TBL] [Abstract][Full Text] [Related]
16. Expression profile of prostate-specific antigen messenger RNA assessed by in situ hybridization is a novel prognostic marker for patients with untreated prostate cancer.
Tsurusaki T; Koji T; Sakai H; Kanetake H; Saito Y
Clin Cancer Res; 1998 Sep; 4(9):2187-94. PubMed ID: 9748138
[TBL] [Abstract][Full Text] [Related]
17. Usefulness of ultrasensitive prostate-specific antigen assay for early detection of biochemical failure after radical prostatectomy.
Nakamura M; Hasumi H; Miyoshi Y; Sugiura S; Fujinami K; Yao M; Kubota Y; Uemura H
Int J Urol; 2005 Dec; 12(12):1050-4. PubMed ID: 16409609
[TBL] [Abstract][Full Text] [Related]
18. Tumour volume is an independent predictor of prostate-specific antigen recurrence in patients undergoing radical prostatectomy for clinically localized prostate cancer.
Nelson BA; Shappell SB; Chang SS; Wells N; Farnham SB; Smith JA; Cookson MS
BJU Int; 2006 Jun; 97(6):1169-72. PubMed ID: 16686706
[TBL] [Abstract][Full Text] [Related]
19. Cytosolic p53 protein and serum p53 autoantibody evaluation in breast cancer. Comparison with prognostic factors.
Dalifard I; Daver A; Larra F
Anticancer Res; 1999; 19(6B):5015-22. PubMed ID: 10697504
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of p53 nuclear accumulation in localized prostate cancer treated with radical prostatectomy.
Quinn DI; Henshall SM; Head DR; Golovsky D; Wilson JD; Brenner PC; Turner JJ; Delprado W; Finlayson JF; Stricker PD; Grygiel JJ; Sutherland RL
Cancer Res; 2000 Mar; 60(6):1585-94. PubMed ID: 10749127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
